<DOC>
	<DOCNO>NCT02278575</DOCNO>
	<brief_summary>The study open control pilot study 6 patient early-onset severe preeclampsia . Patients receive Atenativ addition conventional therapy The patient follow within study three day delivery . Laboratory analyse uterine umbiliacal blood flow determine .</brief_summary>
	<brief_title>Atenativ Effect Uterine Blood Flow Preeclampsia</brief_title>
	<detailed_description>The study open control pilot study 6 patient early-onset severe preeclampsia . Patients receive Atenativ addition conventional therapy The patient follow within study three day delivery . In addition conventional therapy , i.v . administration Atenativ give dosage aim raise plasma level AT initially 120 % ( 1.2 kIU/L ) The goal achieve maintain plasma activity 100 % two week . The dose Atenativ base actual plasma level AT measure 2 hour dose . During first two day treatment plasma sample draw measurement AT activity twice day , 12 hour infusion order monitor dosage . Thereafter study discontinuation AT measure day . The treatment continue two week plasma AT III 100 % ( 1.0 kIU/L ) .Uterine blood flow measure , AT infusion . Demographic data , medical history background data ( age , weight , height , gestational week , smoker , gravidity , parity , previous hypertension , previous medication etc ) record order ensure inclusion criterion meet verify patient identity inclusion status . The week gestation patient include study well week gestation delivery record . The type delivery ( vaginal caesarean section well plan acute ) also recorded.. General haemostatic parameter analyze start treatment every day treatment thereafter least twice week . Special haemostatic parameter Placental growth factor , S-Flt-1 , VEGF Syndecan-1 . They sample start treatment treatment week . The sample collect frozen analyze termination study .</detailed_description>
	<mesh_term>Pre-Eclampsia</mesh_term>
	<mesh_term>Antithrombin III Deficiency</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>1 . Pregnant woman gestational week 23+0 29+0 2 . Severe preeclampsia define international criterion ( 1,2 ) Blood pressure &gt; 160/110 mmHg ( measure twice 30 minute apart ) . proteinuria ( &gt; 5 .0 g/L per 24 hour &gt; 3 + labstick least two random sample six hour apart ) 20th gestational week . Blood pressure &gt; 140/90 mmHg proteinuria &gt; 5.0 g/24 h. preeclampsia ( blood pressure &gt; 140/90 proteinuria &gt; 0.3 g/24 h ) IUGR subjective symptom epigastic pain ( HELLP ) , headache , dizziness visual disturbancies , oligouri &lt; 600 ml/24 h , coagulation disturbancies . 3 . AT level &lt; 0.8 kIE/L 1 . History congenital AT deficiency 2 . Severe preeclampsia demand acute delivery within 24 hour accord investigator judgment 3 . Concomitant administration anticoagulant platelet inhibitor within 2 week 4 . Chronic renal disease 5 . Diabetes melittus gestational diabetes 6 . Intrauterine fetal death 7 . Participation another clinical study 8 . Multiple pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>antithrombin , Atenativ , preeclampsia , blood flow .</keyword>
</DOC>